This initiative is about reform of humanitarian development operations. Its breadth and depth is unprecedented. The mission is to save lives and improve the health of millions of people around the world who are being failed by the humanitarian system, who are negatively impacted by climate change, and who lack access to permanent health infrastructure.
In the past decade, air pollution has driven an exponential increase in the rates of respiratory illness and deaths. According to the World Health Organization, seven million people per year perish from respiratory disease where air pollutants are the causative agent, with no preventive treatment currently available. People in developing nations are significantly impacted, yet have the least access to adequate health services. At the same time, humanitarian development missions lack impact and resources, creating unsustainable dependency rather than building community resilience.
This initiative aims to solve these two interrelated problems, setting a new precedent for humanitarian development operations and driving long term positive social, economic, and ecological impacts.
Researchers at Columbia University, in association with the T.H. Chan School of Public Health at Harvard University, have demonstrated that respiratory disease and death can be prevented and/or mitigated. We will establish a steward-owned B corporation to offer this affordable new drug therapy to people living in poverty and the OECD countries around the world.
Proceeds from the high-volume, low-cost sale of the drug will be directed to a new, independent non-profit medical organization that will develop and operate permanent 2nd tier teaching hospitals in rural and remote locations in developing countries as a free service. Once established, ownership will be transferred to the communities in which they are located. These facilities will be designed, built, and operated at the highest possible environmental standards to offset further climate impacts, and will improve health outcomes, catalyze economic development, and increase the resilience of local communities.
The commitment of this initiative to transformative change includes innovative approaches in all facets of the organizations in order to deliver greater impacts and provide a new model for the humanitarian sector. For the B corporation, this includes everything from its ownership and legal structures, to its internal organizational structures, and an executive team to be comprised of a diverse group of dynamic leaders representing people who have traditionally been systemically and structurally excluded from these positions and opportunities.
In order to allow the organization to operate independently in pursuit of its mission, initial capital for the B Corporation are raised from private family offices aligned with humanitarian principles and focused on women’s advancement, health, and climate change. The business model for the non-profit organization, in addition to the revenue from the sales of the drug, will mirror that of Medecins Sans Frontieres in order to minimize the risk of government or corporate influence.
We are at the beginning of a long and arduous journey that will demand the best and the brightest. Those that suffer on the ground deserve no less.
THE POSITIONS
The Partnership Officers (3) will play a critical role in developing and maintaining relationships with stakeholders, actors and donors in the Asia, Europe, and North American regions to advance the mission. The POs are the face of the organization and will work closely with senior leadership to build a culture based on the core principles of humanitarianism.
RESPONSIBILITIES
The POs report to the Chief Financial Officer.
The POs must possess the following demonstrable characteristics:
QUALIFICATIONS
WORKING CONDITIONS
SWG is the name of the working group that will launch this initiative, which is currently an early-stage start-up. Until successful initial capital funding is in place, working group members will work on a voluntary and uncompensated part-time, as-available basis.
The organization is based in Geneva, Switzerland. The candidates will be based in Asia, Europe, or North America, and travel to Geneva as required.
COMPENSATION AND BENEFITS
Upon successful initial capital raising, a highly competitive base salary plus employee share compensation, and generous benefits.
INTERVIEW AND SELECTION
The selection process is rigorous, assessing the capacity of candidates to serve in alignment with advancing the mission. Candidates will undergo multiple stages, including character assessments, and panel interviews.
To apply, please submit your cover letter and CV/resume.
Please be sure to indicate you saw this position on Globaljobs.org
